Study title:
Schellong-G, Potter-R, Bramswig-J, Wagner-W, Prott-F-J, Dorffel-W, Korholz-D, Mann-G, Rath-B, Reiter-A, Weissbach-G, Riepenhausen-M, Thiemann-M, Schwarze-E-W.
Dr. G. Schellong, Univ.-Kinderklinik, Albert-Schweitzer-Strasse 33, D-48129 Munster, Germany
e-mail: schellon@uni-muenster.de.
High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: The German-Austrian multicenter trial DAL-HD-90.
Journal of Clinical Oncology {J-CLIN-ONCOL}, 1999, Vol/Iss/Pg. 17/12
(3736-3744), ISSN: 0732-183X.Schellong-G, Potter-R, Bramswig-J, Wagner-W, Prott-F-J, Dorffel-W, Korholz-D, Mann-G, Rath-B, Reiter-A, Weissbach-G, Riepenhausen-M, Thiemann-M, Schwarze-E-W.
Dr. G. Schellong, Univ.-Kinderklinik, Albert-Schweitzer-Strasse 33, D-48129 Munster, Germany
e-mail: schel...
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Neoplasms [C04]
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: PROCARBAZINE |
ATC code: |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|